+

TN2009000471A1 - Composes amino-heterocycliques - Google Patents

Composes amino-heterocycliques

Info

Publication number
TN2009000471A1
TN2009000471A1 TNP2009000471A TN2009000471A TN2009000471A1 TN 2009000471 A1 TN2009000471 A1 TN 2009000471A1 TN P2009000471 A TNP2009000471 A TN P2009000471A TN 2009000471 A TN2009000471 A TN 2009000471A TN 2009000471 A1 TN2009000471 A1 TN 2009000471A1
Authority
TN
Tunisia
Prior art keywords
amino
heterocyclic compounds
formula
compounds
schizophrenia
Prior art date
Application number
TNP2009000471A
Other languages
English (en)
Inventor
Patrick Robert Verhoest
Lafrance Caroline Proulx
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39672073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of TN2009000471A1 publication Critical patent/TN2009000471A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)

Abstract

La présente invention propose desc omposés inhibiteurs de PDE9 de formule (I), et leurs sels pharmaceutiquement acceptables, formule dans laquelle R, R1, R2 et R3 sont tels que définis dans le présent mémoire, des compositions pharmaceutiques contenant les composés de formule I; et leurs utilisations dans le traiement de troubles neurodégéneratifs et cognitifs, tels que la maladie d'Alzheimer et la schizophrénie sont également proposées.
TNP2009000471A 2007-05-11 2009-11-06 Composes amino-heterocycliques TN2009000471A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91733307P 2007-05-11 2007-05-11
PCT/IB2008/001125 WO2008139293A1 (fr) 2007-05-11 2008-05-05 Composés amino-hétérocycliques

Publications (1)

Publication Number Publication Date
TN2009000471A1 true TN2009000471A1 (fr) 2011-03-31

Family

ID=39672073

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000471A TN2009000471A1 (fr) 2007-05-11 2009-11-06 Composes amino-heterocycliques

Country Status (44)

Country Link
US (1) US7964607B2 (fr)
EP (1) EP2152712B1 (fr)
JP (1) JP4579346B2 (fr)
KR (1) KR101222330B1 (fr)
CN (1) CN101687876B (fr)
AP (1) AP2524A (fr)
AR (1) AR066502A1 (fr)
AT (1) ATE540954T1 (fr)
AU (1) AU2008249750B2 (fr)
BR (1) BRPI0811280B8 (fr)
CA (1) CA2687035C (fr)
CL (1) CL2008001374A1 (fr)
CO (1) CO6241157A2 (fr)
CR (1) CR11095A (fr)
CU (1) CU23834B1 (fr)
CY (1) CY1112332T1 (fr)
DK (1) DK2152712T3 (fr)
DO (1) DOP2009000258A (fr)
EA (1) EA016510B1 (fr)
EC (1) ECSP099728A (fr)
ES (1) ES2377849T3 (fr)
GE (1) GEP20125405B (fr)
GT (1) GT200900294A (fr)
HK (1) HK1142595A1 (fr)
HR (1) HRP20120105T1 (fr)
IL (1) IL201977A (fr)
MA (1) MA31373B1 (fr)
ME (1) ME00954B (fr)
MX (1) MX2009011830A (fr)
MY (1) MY147330A (fr)
NI (1) NI200900204A (fr)
NZ (1) NZ580904A (fr)
PA (1) PA8779901A1 (fr)
PE (1) PE20090247A1 (fr)
PL (1) PL2152712T3 (fr)
PT (1) PT2152712E (fr)
RS (1) RS52166B (fr)
SI (1) SI2152712T1 (fr)
SV (1) SV2009003411A (fr)
TN (1) TN2009000471A1 (fr)
TW (1) TWI362262B (fr)
UA (1) UA94660C2 (fr)
WO (1) WO2008139293A1 (fr)
ZA (1) ZA200907776B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
EP2217602B1 (fr) 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH Dérivés 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one et leur utilisation comme modulateurs de pde9a pour le traitement de troubles cns
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US9079905B2 (en) 2008-09-08 2015-07-14 Boehringer Ingelheim International Gmbh Compounds for the treatment of CNS disorders
SI2540297T1 (sl) 2008-11-19 2015-08-31 Forum Pharmaceuticals Inc. Zdravljenje kognitivne motnje z (R)-7-Kloro-N-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid in farmacevtsko nje sprejemljivih soli
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
JP5542196B2 (ja) 2009-03-31 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−複素環−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａモジュレーターとしてのそれらの使用
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2485771A4 (fr) * 2009-10-08 2014-11-12 Intra Cellular Therapies Inc Traceurs ciblant la phosphodiestérase 1 et méthodes associées
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
SG187081A1 (en) 2010-08-12 2013-03-28 Boehringer Ingelheim Int 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
DK2615089T3 (en) 2010-09-07 2016-06-06 Astellas Pharma Inc Pyrazoloquinolinforbindelser
PL2619208T3 (pl) * 2010-09-20 2017-03-31 Ironwood Pharmaceuticals, Inc. Związki imidazotriazynonu
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) * 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
PH12014500580A1 (en) 2011-10-07 2014-04-28 Eisai R&D Man Co Ltd Pyrazoloquinoline derivative
US9643970B2 (en) 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
AP2014007820A0 (en) * 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
EP2828262A4 (fr) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc Composés d'imidazotriazinone
MX358512B (es) 2012-05-08 2018-08-24 Forum Pharmaceuticals Inc Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
KR20150027267A (ko) 2012-06-29 2015-03-11 화이자 인코포레이티드 LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
WO2014024125A1 (fr) 2012-08-08 2014-02-13 Celon Pharma S.A. Dérivés pyrazolo[4,3-d]pyrimidin-7(6h)-one comme inhibiteurs de pde9
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2982675B1 (fr) 2013-04-05 2017-08-16 Eisai R&D Management Co., Ltd. Sel de dérivé de pyrazoloquinoline et son cristal
RU2655172C2 (ru) 2013-04-05 2018-05-24 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Пиридинилпиразолохинолиновые соединения
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
EP3083618B1 (fr) 2013-12-17 2018-02-21 Pfizer Inc Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
EP3193878B1 (fr) * 2014-09-17 2021-01-06 Intra-Cellular Therapies, Inc. Dérivés de 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one en tant qu'inhibiteurs de phosphodiestérase 1 (pde1) pour le traitement de maladies, troubles ou blessures du sytème nerveux central (snc)
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
EP3226862B1 (fr) 2014-12-06 2020-07-08 Intra-Cellular Therapies, Inc. Composés inhibiteurs de la phosphodiestérase 2 (pde2)
CN107205999B (zh) 2014-12-06 2021-08-03 细胞内治疗公司 有机化合物
EP3237401B1 (fr) 2014-12-22 2019-03-06 Pfizer Inc Antagonistes de récepteur ep3 de prostaglandine
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
SI3303339T1 (sl) 2015-07-07 2021-05-31 H. Lundbeck A/S Zaviralci PDE9 z imidazo triazinonskim ogrodjem in imidazo pirazinonskim ogrodjem za zdravljenje perifernih bolezni
JP6873980B2 (ja) 2015-09-14 2021-05-19 ファイザー・インク ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
WO2017048720A1 (fr) 2015-09-15 2017-03-23 Praxis Biosciences, Llc Promédicaments de fencamfamine
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
EP3436083A4 (fr) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
TWI729109B (zh) * 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
IL295973A (en) 2016-07-06 2022-10-01 H Lundbeck As pde9 inhibitors for the treatment of peripheral diseases
WO2018073251A1 (fr) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
RU2019109039A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств
AU2017350477A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
WO2018125810A1 (fr) 2016-12-28 2018-07-05 Dart Neuroscience, Llc Composés pyrazolopyrimidinone substitués en tant qu'inhibiteurs de pde2
SI3630772T1 (sl) * 2017-05-26 2024-05-31 Cardurion Pharmaceuticals, Inc., Postopki izdelave in uporabe zaviralcev pde9
US11833146B2 (en) 2017-06-01 2023-12-05 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
EP3630113A4 (fr) 2017-06-01 2021-02-24 Eisai R&D Management Co., Ltd. Composition pharmaceutique comprenant un inhibiteur de pde9
US11147803B2 (en) 2017-06-01 2021-10-19 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
CN111051308A (zh) 2017-06-08 2020-04-21 默沙东公司 吡唑并嘧啶pde9抑制剂
EP3717488B1 (fr) 2017-11-27 2021-09-29 Dart NeuroScience, LLC Composés furanopyrimidine substitués utilisés en tant qu'inhibiteurs de pde1
WO2019152697A1 (fr) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Nouvelles utilisations
CN110357888A (zh) * 2018-04-09 2019-10-22 南京药捷安康生物科技有限公司 杂环磷酸二酯酶抑制剂及其用途
HUE065709T2 (hu) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái
CN112996512B (zh) 2018-08-31 2025-01-03 卡都瑞恩医药公司 用于治疗镰状细胞病的pde9抑制剂
CN113194955A (zh) * 2018-10-21 2021-07-30 细胞内治疗公司 新用途
KR102706457B1 (ko) * 2018-12-06 2024-09-11 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CN111471059B (zh) 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
EP4297868A4 (fr) 2021-02-23 2025-01-08 Hoth Therapeutics Inc Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
CA3242577A1 (fr) * 2021-12-16 2023-06-22 Pfizer Inc. Formes solides de composes pyrazolo[3,4-d]pyrimidine
JP2025508714A (ja) * 2022-02-16 2025-04-10 デューク ストリート バイオ リミテッド 医薬化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
HUP0401998A2 (hu) * 2001-11-02 2005-01-28 Pfizer Products Inc., PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
AU2003253915A1 (en) * 2002-07-12 2004-02-02 Massachusetts Institute Of Technology Reconfigurable microphotonics devices via deformable membrane platform
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7051174B2 (en) * 2002-09-24 2006-05-23 International Business Machines Corporation Method, system, and program for restoring data in cache
WO2004037176A2 (fr) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones et derives de celles-ci comme inhibiteurs du facteur xa
US7111287B2 (en) * 2003-01-10 2006-09-19 International Business Machines Corporation Global processor resource assignment in an assembler
ATE368666T1 (de) 2003-03-18 2007-08-15 Jordanian Pharmaceutical Mfg Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
CN1894234A (zh) 2003-03-25 2007-01-10 武田药品工业株式会社 二肽基肽酶抑制剂
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine

Also Published As

Publication number Publication date
WO2008139293A1 (fr) 2008-11-20
IL201977A0 (en) 2010-06-16
CU20090184A7 (es) 2011-07-11
JP4579346B2 (ja) 2010-11-10
MA31373B1 (fr) 2010-05-03
EA200901373A1 (ru) 2010-06-30
PL2152712T3 (pl) 2012-05-31
CN101687876B (zh) 2012-12-12
CR11095A (es) 2009-12-04
TWI362262B (en) 2012-04-21
DOP2009000258A (es) 2010-05-15
UA94660C2 (en) 2011-05-25
EP2152712B1 (fr) 2012-01-11
CA2687035C (fr) 2011-09-20
BRPI0811280B8 (pt) 2021-05-25
EP2152712A1 (fr) 2010-02-17
ECSP099728A (es) 2009-12-28
GEP20125405B (en) 2012-02-27
CL2008001374A1 (es) 2008-11-14
GT200900294A (es) 2011-08-29
HK1142595A1 (en) 2010-12-10
TW200902015A (en) 2009-01-16
NZ580904A (en) 2012-02-24
US20090030003A1 (en) 2009-01-29
ATE540954T1 (de) 2012-01-15
NI200900204A (es) 2010-03-11
PT2152712E (pt) 2012-02-29
KR20100007985A (ko) 2010-01-22
BRPI0811280A2 (pt) 2015-01-20
AU2008249750A1 (en) 2008-11-20
ES2377849T3 (es) 2012-04-02
BRPI0811280B1 (pt) 2021-05-11
CU23834B1 (es) 2012-10-15
CO6241157A2 (es) 2011-01-20
RS52166B (en) 2012-08-31
MX2009011830A (es) 2009-11-13
KR101222330B1 (ko) 2013-01-15
JP2010526863A (ja) 2010-08-05
AR066502A1 (es) 2009-08-26
EA016510B1 (ru) 2012-05-30
MY147330A (en) 2012-11-30
AP2009005048A0 (en) 2009-12-31
IL201977A (en) 2014-07-31
PE20090247A1 (es) 2009-03-13
CY1112332T1 (el) 2015-12-09
SV2009003411A (es) 2010-05-21
DK2152712T3 (da) 2012-03-26
CA2687035A1 (fr) 2008-11-20
ME00954B (fr) 2012-06-20
PA8779901A1 (es) 2008-12-18
US7964607B2 (en) 2011-06-21
SI2152712T1 (sl) 2012-03-30
ZA200907776B (en) 2011-01-26
AP2524A (en) 2012-12-04
CN101687876A (zh) 2010-03-31
HRP20120105T1 (hr) 2012-02-29
AU2008249750B2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
TN2009000471A1 (fr) Composes amino-heterocycliques
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
ATE483706T1 (de) Weitere heteropolycyclische verbindungen und deren verwendung als antagonisten des metabotropen glutamatrezeptors
MA27438A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA26875A1 (fr) Composes azapolycycliques a noyau aryle condensé
MA28747B1 (fr) Dérivés de pyridine
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
TW200607807A (en) Macrocyclic beta-secretase inhibitors
MA29926B1 (fr) Derives de pyrazine
MA29791B1 (fr) Composes therapeutiques.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MXPA06012640A (es) Compuestos de morfolina.
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
EP1817312A4 (fr) Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer
ATE507226T1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
EP2073635A4 (fr) Inhibiteurs de spiropipéridine macrocyclique de bêta-secrétase pour le traitement de la maladie d'alzheimer
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载